KOL Mapping for Medtech Launches: Tiering Surgeons by Influence, Not Followers

When a medtech company prepares an orthopaedic launch in India, the first list that gets drawn up is usually a list of surgeons with large social followings. It is easy to build and easy to present. It is also a poor predictor of who other surgeons actually listen to when they decide whether to adopt a new implant, instrument or technique.

This article is for medtech marketing and medical affairs leads, and for the agencies that support them. It sets out a scoring matrix for key opinion leader (KOL) mapping built on four signals of professional influence: publications, society roles, training volume and peer referral. It also covers how to record and disclose honoraria, because a map is only useful if the engagement that follows it is defensible.

A caution before the method. This is a framework for structuring judgement, not a validated model, and the weights below are illustrative. Your medical affairs and compliance teams must review the final design and every engagement against current law and company policy.

Why follower count fails as a proxy

A surgeon's audience on a social platform measures reach among whoever follows them. For a device launch, the audience that matters is other surgeons and the hospital teams that approve purchases. A surgeon with a large public following may be admired by patients and still have little pull with a hospital's orthopaedic department. The opposite also happens: a senior surgeon with a modest public profile may train fellows from several states, chair a session at the national conference and be the person colleagues phone before trying a new approach.

Followers also tell you nothing about clinical fit. A launch of a revision hip system needs surgeons who do revisions. A knee navigation tool needs high-volume arthroplasty surgeons who will tolerate a learning curve. Reach on a platform does not capture either.

In a regulated setting there is a second problem. Selecting advisers because they are popular, rather than because they have relevant expertise, makes it harder to justify any payment you make them. Under the Uniform Code for Marketing Practices in Medical Devices 2024, notified by the Department of Pharmaceuticals in September 2024, companies are restricted from giving gifts, cash and hospitality to healthcare professionals, and consultancy arrangements need to be legitimate. A transparent selection method is part of that defence.

The four signals

1. Scholarly output

Count what a surgeon has published, but read it. Pull the surgeon's record from PubMed and Google Scholar, and note the topic of each paper, not just the total. Ten case reports in an unrelated subspecialty count for less than three registry analyses on the procedure your device supports.

Record: number of indexed papers on the relevant procedure in the last five years, first or senior authorship, and whether they have contributed to guidelines, consensus statements or textbook chapters. Be wary of raw citation counts; a single widely cited multi-author paper can inflate a profile.

2. Society and institutional roles

Professional bodies confer a form of peer endorsement. Look at office-bearer roles in national and state orthopaedic associations, subspecialty societies (arthroplasty, spine, sports medicine, trauma), editorial board positions, and examiner or faculty roles at national board and university programmes. Conference programme committees are another useful indicator, because the committee chose who speaks.

Record the role, the body, the year and whether it is current. A past president from fifteen years ago has lower current weight than a sitting conference organiser.

3. Training volume and teaching reach

Influence in surgery travels through training. Ask how many fellows, residents and visiting surgeons the person trains each year, whether they run cadaveric workshops, and whether their department is a recognised training centre. Surgical case volume also matters for credibility on technique, but treat volume with care: it should come from the surgeon or hospital, not be inferred, and it must not be used in any patient-facing material.

Record: teaching posts, fellowship programmes, workshop faculty roles, and approximate annual volume of the relevant procedure as supplied by the surgeon.

4. Peer referral and nomination

The fourth signal is the one most teams skip. Ask a sample of surgeons, through your medical science liaisons or a neutral interviewer, a simple question: whom would you call for advice on this procedure? Count nominations, and note whether the nominators are themselves credible and independent from one another. A name that appears from several cities and several institutions carries more weight than one nominated repeatedly by a single hospital.

Peer nomination also catches regional influencers who are invisible in publication databases but trusted by surgeons in their district.

A worked scoring matrix

Below is a hypothetical matrix for an orthopaedic launch. The weights add up to 100 points. They are illustrative, and your team should set its own after discussing which signals matter most for the product.

Apply a clinical-fit gate before totalling the score. A surgeon who does not perform the procedure scores zero for the project however high the other numbers go. Then place surgeons in tiers by total. In this hypothetical scheme, 80 and above is Tier 1, 55 to 79 is Tier 2, and 30 to 54 is Tier 3. Below that, keep the person on the map but outside the launch plan.

What each tier is for

• Tier 1: national voices. A handful of surgeons who shape guidelines and conference agendas. Engagement is long-term and scientific: advisory input on clinical evidence, trial design or training curricula, never a promotional role in disguise.
• Tier 2: regional leaders. Surgeons who train others in a city or state. They matter for proctoring, case observation and peer-to-peer education events.
• Tier 3: early adopters. High-volume surgeons who try new technology and give practical feedback. They are the reference points for the next group of adopters.

Use the tiers to plan activity, not to decide payment. Fees should come from a documented fair-market-value method set by compliance, applied to the work actually done.

A small hypothetical example

Imagine a company launching a cementless knee system. Medical affairs lists 60 surgeons. After the clinical-fit gate, 41 remain. One surgeon scores high on publications and society roles but trains few fellows, giving a total of 78. Another has a smaller publication record, runs a recognised fellowship, and is nominated by surgeons in four cities, giving 82. The scoring puts the second surgeon in Tier 1 and the first in Tier 2, where a follower-count approach might have ranked them the other way round. This is an illustration of how the matrix behaves, not a result.

Validate the scores before you rely on them

Treat the first pass as a hypothesis. Run a short validation:

1. Have two scorers rate the same twenty surgeons independently and compare. Large gaps point to unclear scoring rules.
2. Show the tier lists to two or three medical advisers who are not on the list and ask what looks wrong.
3. Check for conflicts: surgeons already engaged by a competitor, with equity interests, or who work in a hospital with a purchasing relationship.
4. Re-score twice a year. Roles change, and so does clinical practice.

Keep the data in a controlled system with dates and sources next to each score, so that anyone can see why a surgeon is in a tier.

Recording and disclosing honoraria

Any payment, travel support or in-kind benefit needs a written agreement, a described scope of work, a fee set by a documented method and a record of the work done. The 2024 device code is reported to bar cash grants, gifts and personal hospitality for healthcare professionals, and to require disclosure of spend on conferences and seminars. Check the current text and the company's own policy with legal counsel, because a code this new is likely to be clarified by guidance.

The surgeon has obligations too. India's medical councils restrict how doctors may accept benefits and endorse products, and the NMC rules on advertising and conduct apply to what they say publicly. Our summary of the NMC advertising guidelines and the NMC compliance handbook explain the practical limits for doctors. Build the agreement so that the surgeon can comply: no product endorsement in public channels, no patient-directed promotion, and no pressure to prescribe or use a product.

Disclosure should be a habit, not a defence. Require speakers and authors to state their relationship with the company whenever they present or publish. The medical-journal convention is a good model; the ICMJE disclosure form shows the categories journals ask about. In the United States, the Open Payments programme publishes company payments to physicians. India has no equivalent public register for devices, so many companies publish their own disclosure to build trust.

Failure modes to watch

• Mapping the same names everyone else does. If every competitor courts the same five surgeons, the map has told you nothing. Look for Tier 2 and 3 names.
• Confusing access with influence. A surgeon your sales team knows well may not be the one peers follow.
• Scoring on self-reported data only. Cross-check publications and roles against public sources.
• Using the map to reward prescribing. The map is for scientific exchange. Linking tiers to sales volume invites a compliance problem.
• Ignoring non-surgeon influence. Anaesthetists, physiotherapists, nurses and hospital purchasing teams shape adoption too. Map them separately.

Where to start

1. Fix the clinical-fit criteria with medical affairs: which procedures, which patient types.
2. Agree the weights and scoring guide in writing, and have compliance sign off.
3. Build a long list from conference programmes, society rosters and publication searches, not from social media.
4. Score independently with two raters, then reconcile.
5. Run peer-nomination interviews with a neutral interviewer.
6. Assign tiers, plan activity per tier, and set fees through the compliance method.
7. Record every engagement and disclosure in one register.

Our KOL marketing service works from this kind of evidence-based map, and the glossary entry on KOLs gives the plain definition. For the orthopaedic context, see our notes on orthopaedic marketing for joint replacement.